Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q92871
UPID:
PMM1_HUMAN
Alternative names:
PMMH-22
Alternative UPACC:
Q92871; A8K003; Q92586
Background:
Phosphomannomutase 1 (PMM1), also known by its alternative name PMMH-22, plays a pivotal role in cellular processes by being involved in the synthesis of GDP-mannose and dolichol-phosphate-mannose. These compounds are essential for numerous mannosyl transfer reactions. Additionally, PMM1 may have a role in the degradation of glucose-1,6-bisphosphate in ischemic brain conditions, highlighting its importance in metabolic pathways.
Therapeutic significance:
Understanding the role of Phosphomannomutase 1 could open doors to potential therapeutic strategies. Its involvement in critical biochemical pathways suggests that targeting PMM1 could offer new avenues for treating metabolic disorders or managing ischemic brain injuries.